GlassScriptPhysician profile
Maria P Rumsey
NPI 1023295516
$48,277.77
in general payments reported to CMS, 2019-2025
41 companies · $6,284 in 2025
The $6,284 reported for 2025 was more than what 93% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,740 · 2020: $2,070 · 2021: $3,283 · 2022: $3,162 · 2023: $12K · 2024: $18K · 2025: $6,284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Food and Beverage: $7,406 · Travel and Lodging: $1,622.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26,995.00 |
| Food and Beverage | $7,405.69 |
| Travel and Lodging | $1,621.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $24,566.55 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $5,390.00 | 2023-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $4,006.05 | 2019-2025 | Eliquis, Camzyos |
| Boston Scientific Corporation | $2,189.32 | 2019-2024 | Watchman Flx |
| Abbott Laboratories | $1,385.90 | 2021-2025 | Amplatzer Amulet, Cardiomems |
| Cardiologs Technologies | $1,250.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $1,156.22 | 2019-2025 | |
| Amgen INC. | $1,054.14 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $1,028.33 | 2019-2024 | Xarelto |
| Pfizer INC. | $726.59 | 2019-2025 | |
| Novo Nordisk INC | $693.93 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $553.65 | 2019-2025 | Farxiga, Brilinta |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $414.94 | 2019-2024 | Lifevest |
| Edwards Lifesciences Corporation | $412.34 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $334.33 | 2019-2025 | Onpattro, Amvuttra |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Rumsey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.